stars 1 stars 2 stars 3

Vaxxel develops novel and proprietary live-attenuated vaccines candidate against bronchiolitis and pneumonia and in particular against human Metnapneumovirus and against human Respiratory Virus. Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), Pr. Guy Boivin of the University of Laval (Quebec), by Denis Cavert, President of Vaxxel.

Vaxxel Questions

1 people are employed at Vaxxel.

Vaxxel is based in Villeurbanne, Auvergne-Rhône-Alpes.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users